Arkansas Children's Care Network, Arkansas Children's Hospital, Little Rock, Arkansas.
Biostatistics Core, Arkansas Children's Research Institute, Little Rock, Arkansas.
Respir Care. 2023 Nov;68(11):1540-1545. doi: 10.4187/respcare.10534. Epub 2023 Jun 6.
Inhaled corticosteroids (ICSs) are a fundamental pillar of most regimens for long-term control of persistent asthma. Poor adherence to ICS medication is a common problem in the asthma population that can lead to poor asthma control. We hypothesized that conducting a follow-up telephone call after general pediatric clinic visits for asthma would improve refill persistence.
We conducted a prospective cohort analysis of pediatric and young adult subjects followed in our pediatric primary care clinic for asthma on ICS medication found to have poor ICS refill persistence. This cohort received a follow-up telephone outreach call 5-8 weeks after the clinic visit. The primary outcome measure was refill persistence with regard to ICS therapy.
There were 289 subjects who met the inclusion criteria and did not meet any exclusion criteria for the study ( = 131 in the primary cohort, = 158 in the post-COVID cohort). The mean ICS refill persistence increased significantly for subjects in the primary cohort (39.4 ± 30.8% post intervention vs 32.4 ± 19.7% pre intervention) ( = .02) but not in the post-COVID cohort (36.4 ± 25.6% post intervention vs 38.9 ± 21.0% pre intervention) ( = .26). There was not a statistically significant change in hospitalizations after the intervention in either the primary or the post-COVID cohorts ( = .08 and .07, respectively). Systemic corticosteroid courses and emergency department visits decreased significantly post intervention ( = .01 and = .004, respectively) in the primary group but not in the post-COVID group ( = .75 and = .16, respectively).
These results suggest that telephone outreach after out-patient clinic visits for asthma may have short-term benefit in ICS refill persistence; however, the effect size was small.
吸入性皮质类固醇(ICSs)是大多数持续性哮喘长期控制方案的重要支柱。哮喘患者普遍存在ICS 药物依从性差的问题,这可能导致哮喘控制不佳。我们假设,在儿科普通诊所就诊后进行随访电话,可以提高药物的续用率。
我们对在我们的儿科初级保健诊所接受 ICS 药物治疗的哮喘儿童和青年患者进行了前瞻性队列分析,这些患者的 ICS 药物续用率较低。该队列在就诊后 5-8 周接受了随访电话外呼。主要观察指标是 ICS 治疗的续用率。
共有 289 名符合纳入标准且无任何排除标准的患者(原发性队列为 131 名,COVID-19 后队列为 158 名)。原发性队列患者的 ICS 续用率显著提高(干预后为 39.4±30.8%,干预前为 32.4±19.7%)( =.02),但 COVID-19 后队列无显著变化(干预后为 36.4±25.6%,干预前为 38.9±21.0%)( =.26)。在原发性和 COVID-19 后队列中,干预后住院治疗均无统计学显著变化(分别为 =.08 和.07)。原发性组的全身皮质类固醇疗程和急诊就诊次数在干预后显著减少(分别为 =.01 和 =.004),但 COVID-19 组无显著变化(分别为 =.75 和 =.16)。
这些结果表明,哮喘门诊就诊后进行电话外呼可能对 ICS 续用率有短期益处,但效果较小。